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Nicolaus Kr€oger,1 Koichi Miyamura,2 Michael R. Bishop3Minimal residual disease (MRD), both before and after transplantation, is a clinically important yet relatively
poorly defined aspect of allogeneic hematopoietic stem cell transplantation (alloHSCT). The clinical rele-
vance of MRD in the context of alloHSCT has been demonstrated by its association with the development
of clinical relapse. However, with the possible exception of chronic myeloid leukemia (CML), the specific
techniques, timing, frequency, and clinical utility, relative to improvement in patient outcomes, for monitoring
MRD in the setting of alloHSCT has yet to be clearly defined. A concise overview of monitoring techniques
for detecting MRD, as well as treatment strategies and biological and clinical research initiatives for MRD sug-
gested by the National Cancer Institute First International Workshop on the Biology, Prevention, and Treat-
ment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation, is covered in this article.
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Minimal residual disease (MRD), in the setting of
allogeneic hematopoietic stem cell transplantation
(alloHSCT), poses several interesting questions and
complex challenges. The relevance of these questions
and challenges is personified by the relationship be-
tween MRD and the risk of relapse, which is primary
cause of treatment failure and death after alloHSCT
[1]. The clinical relation of posttransplant MRD with
relapse, particularly in relationship to chronic myeloid
leukemia (CML), was recognized early with develop-
ment of cytogenetic and molecular techniques of
detection [2]. The clinical relevance of MRD has
been further recognized with the increased use of non-
myeloablative and reduced-intensity conditioning
(RIC) regimens, with which relapse is even a greater
clinical problem [3,4].
Despite the clear association of MRDwith relapse,
the clinical relevance ofMRD in the alloHSCT setting
remains to be determined. First and foremost, the1University Hospital Hamburg-Eppendorf, Hamburg,
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6/j.bbmt.2010.10.031definition of MRD needs to be defined for each dis-
ease, and needs to be distinguished from what we cur-
rently refer to as ‘‘remission’’ or ‘‘relapse.’’ The
detection of persistent disease posttransplant by im-
munophenotypic measures has significantly different
implications for patients with acute lymphocytic leu-
kemia (ALL) compared to someone with persistent
chronic lymphocytic leukemia (CLL) [5,6]. Similarly,
the molecular detection of a cytogenetic abnormality
in the posttransplant is markedly different for
a patient transplanted with chronic myeloid leukemia
(CML) compared to a patient with acute myeloid
leukemia (AML) [7]. Second, when and how often we
should be using available techniques for a specific dis-
ease remains to be defined. This applies not only to the
posttransplant setting, but also to the pretransplant
setting, where multiple studies have demonstrated
the prognostic significance of MRD prior to condi-
tioning [8]. As the majority of relapses occur within
the first 6 months after transplantation [1], it is impor-
tant to determine the frequency of monitoring for re-
current disease within this posttransplant period. If
we can determine when and how often, the next ques-
tion is what tests should we be performing and are
those tests adequately sensitive, specific, reproducible,
practical, and economical. Finally, and most impor-
tantly, does monitoring for MRD make a clinical dif-
ference? There is sufficient evidence that detection of
MRD provides prognostic information. However,
does this information result in clinical decisions, rela-
tive to choice of conditioning regimen or stem cell
product relative to detection of pretransplant MRD
or intervention (eg, withdrawal of immune suppression
Biol Blood Marrow Transplant 17:S94-S100, 2011 S95MRD and AlloHSCTor donor lymphocyte infusion) that result in improved
outcomes? These remain essential questions for which
there are relatively limited data and recommendations,
with the possible exceptions of CML and ALL, and
even with these diseases, there remains a need for
further investigation.
This manuscript attempts to provide a concise
overview of many of these issues. Specifically, it at-
tempts to address methods for monitoring MRD and
strategies to clinically manage patients once MRD is
detected. In addition, a brief summary is provided on
the National Cancer Institute First International
Workshop on the Biology, Prevention, and Treatment
of Relapse after Allogeneic Hematopoietic Stem Cell
Transplantation, which attempted to address in a for-
mal manner many of the issues described above.MONITORING MRDAFTER ALLOSCT
Improved supportive care, the introduction of RIC
regimen, and careful donor selection have substantially
decreased the nonrelapse mortality (NRM) after
alloHSCT in recent years, and therefore relapse
has become the leading cause of death following
alloHSCT. Furthermore, as inferred above, relapse
remains the primary cause of death among patients sur-
viving more than 2 years after alloHSCT [9]. Despite
improved understanding of the biology that underlies
the graft-versus-leukemia/tumor (GVL/GVT) effect,
the relapse rate has not decreased over the past 20 years
[10,11]. It is obvious that relapse after alloHSCT
evolves from residual disease that escaped the
preceding conditioning regimen as well as the graft-
versus-malignancy effect.
Newmethodologic and technologic advances allow
sensitive detection of MRD and early recognition
of recurrence after alloHSCT. This is of clinical
importance because intervention prior to florid relapse
improves outcome for certain hematologic malig-
nancies [12,13]. Standard diagnostic criteria that
are widely employed in the definition of relapse for
the different hematologic malignancies are based on
morphologic bone marrow investigations, imaging,
and/or specific laboratory findings. After alloHSCT,
more sensitive methods, such as tumor-specific molec-
ular primers, molecular genetics, fluorescence in situ
hybridization (FISH), flow cytometry, and/or chime-
rism analysis, are commonly used to monitor patients
with respect to relapse (Table 1).
Broadly, 2 different approaches are mainly used for
the posttransplant surveillance of disease status: charac-
terizationof chimerism, and specific detectionofMRD.
The latter approach measures the malignant clone di-
rectly, whereas chimerism assessment characterizes
the origin of posttransplant hematopoiesis. For chime-
rism as well as for specific detection of residual disease,a variety of techniques are available, although in gen-
eral, there have been more studies looking directly at
markers of residual tumor than of chimerism [14].
Despite the increasing sensitivity by the described
methods of chimerism determination, because of its
low specificity, this method is not a reliable means of
detecting MRD. The specificity is higher in diseases
that originate from a stem or progenitor cell (eg,
AML, CML), whereas in B cell lymphoma or multiple
myeloma, which originate from a late B cell stage of de-
velopment, the specificity of chimerism to detectMRD
or relapse is low. The lack of specificity might be over-
come partly by performing lineage-specific chimerism
in some diseases such as multiple myeloma [15].
A paradigm for the importance of minimal molec-
ular disease and prediction of relapse after alloHSCT
is CML.Here, it is nowwell established that the detec-
tion of the chimeric BCR-ABL mRNA transcript by
reverse-transcriptase polymerase chain reaction (RT-
PCR) is a powerful predictor of subsequent relapse
[16]. The use of quantitative PCR has greatly increased
the clinical value of monitoring MRD. It could be
demonstrated that the kinetics of BCR-ABL level
over time described impending relapse and response
to donor lymphocyte infusion (DLI). Low or absence
of residual BCR-ABL was associated with a very low
risk of relapse (1%), compared to 75% relapse rate in
CML patients with increasing or persistently high
BCR-ABL levels [17]. The activating mutation
V617F of the JAK2 gene is an obvious target for mon-
itoring MRD in patients with myeloproliferative dis-
orders undergoing alloHSCT. There are emerging
data suggesting that, similar to BCR-ABL in CML,
PCR negativity for JAK2-V617F correlates with pro-
longed remission and that reappearance of a detectable
JAK2-V617F clone is associated with relapse [18].
However, the utility of the available tools in the
monitoring of disease status after alloHSCT has not
yet been fully elucidated across all hematologic malig-
nancies. In AML and myelodysplastic syndromes,
several studies demonstrated the relevance of chime-
rism, and especially its kinetics, for the prediction
of relapse. A variety of genetic markers are available
for MRD in AML such as rearrangements t (15;17)/
PML-RARA, inv(16)/CBFB-MYH11, and t(8;21)/
RUNX1-RUNX1T1, NPM1, FLT3, or MLL-PTD
but have not been studied in a larger cohort of patients.
Methods for MRD monitoring in B- or T-
lymphoid malignancies include PCR techniques aiming
to quantitatively detect disease specific T cell receptor
(TCR) or immunoglobulin (Ig) gene rearrangements.
Multiple studies support the independent prognostic
value of MRD measurements in pediatric and adult
patients with B- and T-lineage ALL. Furthermore,
the risk of relapse appears to be proportional to the level
of MRD, which in some studies was found to be the
most powerful prognostic factor for relapse in
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S96 Biol Blood Marrow Transplant 17:S94-S100, 2011N. Kr€oger et al.multivariate analyses [13]. Similarly, detection of pre-
transplant MRD in pediatric and some adult studies is
highly predictive of relapse following alloHSCT and,
coupled with posttransplant MRD evaluation, may
guide early posttransplant intervention such as early
withdrawal of immunosuppression, administration
of DLI, or addition of posttransplant maintenance
therapy (eg, targeted tyrosine kinase inhibition for
Ph1 ALL).
In CLL, 2 main approaches of MRD assessment
have been followed: flow cytometry, taking advantage
of the unique immunophenotype of CLL, and PCR-
based strategies using the clonal rearrangement of
the hypervariable region of the VH part of the immu-
noglobulin heavy chain gene (CDR3 region). Several
studies showed that MRD assessment after alloHSCT
is predictive for durable freedom from CLL progres-
sion if: (1) MRD levels are below 1  1024 at 1 year
posttransplant, or (2) show decreasing or stable kinet-
ics within the quantitative range. The clinical impact
of MRD detection in different lymphomas is not
identical.
Specific chromosomal translocations detectable by
PCR amplification, particularly t(11;14) and t(14;18)
translocation, are present in mantle cell lymphoma
and follicular lymphoma, respectively, but t(14;18)
translocation is also detectable by PCR at low levels
in 10% to 25% of healthy individuals. For Hodgkin
lymphoma, neither cytogenetics, flow cytometry,
nor molecular testing is helpful for assessing residual
disease [19].
In multiple myeloma, MRD can be detected by
PCR using patient-specific primers derived from the
rearrangement of immunoglobulin heavy-chain genes.
It could be shown that durable PCR-negativity after
allografting had a cumulative risk of relapse at 5 years
of 0%, in comparison to 33% for PCR-mixed patients
and 100% for patients who never achieved PCR-
negativity [20]
Ongoing and further clinical trials investigate
whether sensitive MRD detection will allow for earlier
therapeutic intervention, and it is hoped that treat-
ment prior to overt relapse may improve outcome of
allogeneic stem cell transplantation for hematologic
malignancies.STRATEGIES AND OPTIONS FOR
RECURRENT DISEASE FOLLOWING
ALLOSCT
The clinical significance of MRD after alloHSCT
is different among diseases. MRD has been extensively
studied using the qualitative PCR method during the
early 1990s. Detection of BCR-ABL by PCR in the
first year after alloHSCT for CML patients disappears
in the majority of patients, secondary to ongoing GVT
Biol Blood Marrow Transplant 17:S94-S100, 2011 S97MRD and AlloHSCTeffects; however, detection of MRD after alloHSCT
for Philadelphia chromosome-positive acute lympho-
blastic leukemia (Ph1ALL) is indicative of imminent
hematologic relapse [21-24]. In the case with t(8;21)
AML, MRD after chemotherapy does not always
indicate eventual clinical relapse. In the last decade,
quantitative PCR machines are widely available, and
sequential and quantitative tests of leukemic genes
have become available. With this technique, a rise in
the amount of leukemic genes strongly suggests
clinical relapse in the near future. Also, several
investigators have tried to find thresholds for the
amount of genes that are predictive of clinical relapse.
However, because of a lack of standardization of this
technique, hitherto universal threshold has not been
clarified at any leukemia with the possible exception
of CML.
Clinical Intervention
Because of the limitation of quantitative PCR as
mentioned above, clinical intervention upon the
emergence of MRD has not been well established.
Clinical interventions for early relapse and MRD after
alloHSCT are performed in 2 ways; 1 is adoptive
immunotherapy including DLI and vaccination, and
the other is administration of new agents, which are ex-
pected to preserve normal hematopoietic cells. Several
questions are raised in this clinical setting. First, does
early intervention have more clinical effects than the
intervention performed at hematological relapse? Sec-
ond, does clinical intervention affect the other param-
eters such as graft-versus-host disease (GVHD),
related adverse events, and the subsequent alloHSCT.
Third, which is the better way, prophylactic adminis-
tration or intervention upon MRD, for patients with
a high risk of relapse?
Adoptive Immunotherapy
DLI was first developed for relapsed patients. Al-
though they are dramatically effective for CML, DLI
remains limited of limited utility for patients with
other diseases because of inadequate responses and
toxicity related to GVHD, which occurs in one-third
of patients. As a strategy to reduce the incidence and
severity of GVHD while preserving the GVL effect,
tumor-specific DLI are proposed [25]. A protocol to
generate hematopoietic cell–specific minor antigen
(eg, HA-1, HA-2, ACC-1) specific T cell lines from
mHag-negative donors was studied for adoptive im-
munotherapy. Warren et al. [26] conducted a phase
I/II study to test the toxicity and effectiveness of
CTL clones specific for minor H antigens. However,
this strategy using cloned antigen-specific T cells has
been shown to be ineffective mostly because these cells
could not survive long enough to execute their cyto-
toxic ability in vivo. This problem could be overcomeby: (1) infusion of a relatively young and small number
of memory T cells without extensive expansion in vi-
tro, and (2) infusion of autologous peripheral blood
T cells transduced retrovirally with T cell receptor
a and b cDNA cloned from tumor/minor antigen–
specific T cell clones [27]. The latter approach has
been shown to be promising in the setting of mela-
noma treatment in studies conducted by Rosenberg
and colleagues at the National Cancer Institute [28].
Thus, T cells armed with TCR specific for WT-1,
HA-1, HA-2, and ACC-1 would be great candidates
for adoptive immunotherapy in the very near future.
Another approach studied intensively in the clinical
hematology field is a vaccination using epitope pep-
tides such as WT-1, PR3, MUC-1, NY-ESO-1, and
BCR-ABL fusion polypeptides. In particular, WT-1
is one of the most promising tumor antigens because
WT1 vaccination-driven immunologic responses and
clinical responses, including reduction of leukemic
cells, and the reduction of the M-protein amount in
myeloma, have been reported. Further enhancement
of the efficacy of the WT1 peptide vaccine can be ex-
pected by coadministration of WT1-specific helper
peptide, Th1-inducing adjuvant, or immunosuppres-
sive chemotherapy prior to vaccinations to take advan-
tage of inhibition of regulatory T cells and facilitation
of homeostatic expansion of desired T cells. Adoptive
immune therapies as prophylaxis or preemptive ther-
apy would be performed in the near future.New Agents
Chemotherapy for the patients with recurrent dis-
ease is hampered by the fact that these agents impel the
normal hematopoietic cells, as well as the fact that
tumor cells and tumor-specific agents have long been
desired. Recently, a new molecular-specific targeting
agent has been developed. The specific manner of
these new agents prompts us to use them for earlier
interventions. Nevertheless, most of these tumor-
specific agents exert some effects on normal hemato-
poietic cells and interfere with immunologic functions
after alloHSCT.
Tyrosine kinase inhibitors
Philadelphia chromosome-positive ALL is associ-
atedwithhighly aggressivedisease.AlthoughalloHSCT
is at present the only curative treatment option, hemato-
logic relapse still remains a major obstacle. Recently,
there have been some reports of posttransplant imatinib
administration, but its efficacy and administration
methods are still controversial. Nishiwaki and col-
leagues [29] compared prophylactic administration of
imatinib with intervention upon molecular relapse to
evaluate the effect of posttransplant imatinib adminis-
tration. MRD became positive in both groups, leading
to hematologic relapse. It was therefore concluded that
S98 Biol Blood Marrow Transplant 17:S94-S100, 2011N. Kr€oger et al.posttransplant imatinib administration may not be an
ideal prophylactic treatment for Ph1ALL patients. In
contrast, Ottmann et al. [30] demonstrated that all
Ph1ALL patients who received imatinib upon appear-
ance of BCR-ABL and promptly achieved molecular
response remained in remission for the duration of
imatinib treatment.
Bortezomib
Recently, both conventional chemotherapy and
autologous and alloHSCT combined with new agents,
such as thalidomide, lenalidomide, and bortezomib,
have improved the depth of response and survival of
multiple myeloma patients. However, after transplan-
tation, most patients still harbor residual disease. La-
detto et al. [31] reported the effect of posttransplant
consolidation including bortezomib onMRDdetected
by PCR using tumor-clone–specific primers. Molecu-
lar remissions were achieved in 3% of patients after
autologous HSCT and 18% after consolidation with
bortezomib. It has been proposed that bortezomib in-
creases the expression of Fas and DR5 and enhances
GVT effects, and that this agent also suppresses the ac-
tivity of NFkB, resulting in reduction of inflammatory
cytokines related to graft-versus-host activity [32].
Lenalidomide
Lenalidomide is an immunomodulatory drug
(IMiD) that has multiple effects on myeloma cells and
their microenvironment. Administration of IMiDs for
postautologous HSCT maintenance resulted in pro-
longed progression-free survival (PFS) even in patients
who achieved very good partial response or complete
response before lenalidomide administration. In the al-
loHSCTsetting, lenalidomideplus low-dosedexameth-
asone combination therapy have shown significant
disease and chronic GVHD (cGHVD) control for mye-
loma patients, who relapsed after transplantation [33].
GVHD control with IMiD is still controversial but
a very attractive issue for investigation [34].
Hypomethylating agents
Low-dose 5-azacitidine (5-Aza) was used by inves-
tigators at the M.D. Anderson Cancer Center for pa-
tients with AML/MDS as a maintenance therapy or
salvage therapy upon relapse after alloHSCT; an over-
all survival rate of 90% at 1 year was reported [35].
Additive effects of DLI to 5-Aza were also reported.
The administration of 5-Aza was not associated with
an increased incidence of GVHD. Sanchez-Abarca
et al. [36] reported that 5-Aza inhibits T cell prolifer-
ation and activation, blocking the cell cycle in the
G0 to G1 phase and decreasing the production of
proinflammatory cytokines such as tumor necrosis
factor-a (TNF-a) and interferon-g (IFN-g). They
also reported that administration of 5-Aza after trans-plantation prevented the development of GVHD,
leading to a significant increase in survival in a fully
mismatched bone marrow transplantation mouse
model. Recently, decitabine, another DNA hypome-
thylating agent, was reported to be used in patients
experiencing cytogenetic relapse after alloHSCT [37].
Humanized monoclonal antibodies
Rituximab (anti-CD20 monoclonal antibody) was
used for 9 chronic lymphocytic leukemia patients who
had persistent disease after alloHSCT and underwent
immuno-manipulation to augment GVT effects in-
cluding immunosuppression withdrawal and DLI with
rituximab treatment, and 8 patients had a complete re-
sponse [38]. Alemtuzumab (anti-CD52monoclonal an-
tibody), as well as antithymocyte globulin (ATG), has
been used as a T cell depletion method in alloHSCT.
Because it is reported that the majority of precursor
B-ALL blasts express CD52, and CD52 is expressed
on other ALL cells, alemtuzumab is considered to
potentially contribute to the eradication of MRD [39].
Summary on the Treatment of MRD
For decades, interventions for relapsed patients
have been performed using DLI and chemotherapies;
however, they are a 2-edged sword, hampering normal
hematopoietic cells as well as tumor cells. Recently,
the emergence of new strategies using tumor-specific
DLI and tumor-specific new agents has prompted us
to use these methods before clinical relapse. Some of
them are used as prophylaxis, and some of them are
used upon tumor emergence at molecular level. Trials
confirming these strategies are just beginning, and
there is a need for the definition of MRD. Thus, it is
becoming more and more important that the measure-
ment of MRD becomes standard practice; otherwise,
clinical studies will be somewhat meaningless.NATIONAL CANCER INSTITUTE FIRST
INTERNATIONALWORKSHOP ON THE
BIOLOGY, PREVENTION, AND TREATMENT
OF RELAPSE AFTER ALLOHSCT
As stated above, there is a strong association of
MRD with relapse following alloHSCT. The growing
recognition of relapse as one of the most significant
posttransplant problems led to the organization and
convening of the National Cancer Institute First
International Workshop on the Biology, Prevention,
and Treatment of Relapse after AlloHSCT [40]. The
primary objectives of the Workshop were to review
the current ‘‘state-of-the-science’’ relative to the biol-
ogy, natural history, prevention, and treatment, and
identify the most important biological and clinical
questions that need to be addressed relative to relapse
following alloHSCT.
Biol Blood Marrow Transplant 17:S94-S100, 2011 S99MRD and AlloHSCTThe Workshop, which took place on November 2
and 3, 2009, in Bethesda, Maryland, USA, brought to-
gether an international group of more than 200 basic
and clinical researchers. Over 50 formal presentations
were made by theWorkshop committee members that
addressed both GVT and non-GVT biology, relapse
epidemiology, and natural history, strategies, and ther-
apies for prevention, disease-specific methods, and
strategies for monitoring, and disease-specific treat-
ment of relapse following alloHSCT. These presenta-
tions are available for viewing at https://ccrod.cancer.
gov/confluence/display/NCIRelapse/Presentations1
from1Workshop. Each of the 6 workshop committees
subsequently prepared a ‘‘state-of-the-science’’ manu-
script, which contained their commended research
priorities; these manuscripts were published sequen-
tially during 2010 in the Biology of Blood and Marrow
Transplantation [1,14,19,41-44].
The central Workshop theme was that in its most
simplistic form, relapse occurs because tumor cells are
first able to resist the cytotoxic effects of the condition-
ing regimen. These surviving cells either never re-
spond to initial GVT or they subsequently escape
from GVT effects after initial control.
Central and recurrent research themes included the
necessity to establish biorepositories to collect and store
tumor samples before transplant when possible, and af-
ter transplant, store samples from allografts for analysis,
and collect blood and serum samples at set posttrans-
plant time points and at the time of relapse for study
of immunology related to relapse. Second, there is
a need for more careful study of the natural history of
relapse for specific diseases, particularly in regard to
MRD. To perform such studies, there needs to be
international acceptance of standard definitions and
techniques; it is hoped that the definitions and tech-
niques proposed by the Workshop will be considered
for this purpose. Finally, there needs to be multi-
institutional collaboration in regard to prevention and
treatment of relapse after alloHSCT. A formal sum-
mary of the workshop recommendations will be pre-
sented during the 2011 Tandem Transplant Meetings
Educational Sessions.ACKNOWLEDGMENTS
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